Clinical trial landscape for guided bone regeneration: trend analysis and future perspectives

Yuqing Gui, Xinyue Shen, Hongying Li, Jin Lou, Jiani Cao, Yu Jiang, Zhuojing Luo, Tianxiang Geng, Jingwei XieFrontiers in Dental Medicine 2025 · DOI

TL;DR

This paper analyzes clinical trials in oral and maxillofacial bone regeneration, revealing a significant shift from traditional bone graft and barrier membrane approaches to integrated, multi-component strategies. The research highlights the growing importance of synthetic bone substitutes, advanced bioactive factors like PRF, and novel approaches combining scaffolds, growth factors, and small molecules for personalized bone defect repair.

What Problem Does This Paper Address?

Tooth loss and subsequent alveolar bone resorption create significant challenges for dental implant placement, often necessitating bone regeneration. The traditional approach involves using bone grafts to fill defects and barrier membranes to guide healing by excluding unwanted cells. However, limitations exist with current materials, such as donor site morbidity and limited availability of autografts, immune rejection risks with allografts, and the need for more effective and personalized solutions. This paper addresses the need to understand the current landscape of clinical research in this field, identify emerging trends, and pinpoint future research directions to optimize bone regeneration strategies.

Methods

The authors conducted a systematic analysis of clinical trials registered up to March 2025 across 16 global clinical trial registries. They employed professional search terms related to "bone regeneration" and "osteoconduction" to identify relevant studies. The retrieved trials were then categorized and analyzed based on:

  • Registration year: To track temporal trends.
  • Research phase: To understand the developmental stage of interventions.
  • Material/drug classification: To identify the types of bone graft materials, barrier membranes, bioactive factors, and drugs being investigated.
  • Geographical distribution: To map where research is being conducted.

Statistical analysis involved frequency counts and percentages, with data visualization using bar charts and Sankey charts. Geographic distribution was mapped using Python.

Datasets

The study analyzed data from 16 clinical trial registries, including but not limited to:

  • China Clinical Trial Registration Center
  • U.S. Clinical Trial Registration Platform (clinicaltrials.gov)
  • EU Clinical Trials Register
  • Japan Clinical Trial Registration Platform
  • German Clinical Trial Registration Platform

A total of 787 clinical trials were initially identified, with 522 ultimately included after excluding duplicates and irrelevant studies. No new datasets were introduced; the study relied on publicly available registry data.

Key Insights and Ideas

  • Paradigm Shift: The field is moving beyond the simple "bone graft + barrier membrane" approach towards "multicomponent integration." This signifies a move towards more sophisticated, personalized, and potentially more effective regenerative strategies.
  • Synthetic Dominance: Synthetic bone substitutes are increasingly favored over xenografts, likely due to their customizability, availability, and reduced immunogenicity.
  • PRF's Prominence: Platelet-Rich Fibrin (PRF) has emerged as a highly utilized bioactive adjuvant, often combined with bone graft materials to create "sticky bone" formulations.
  • Emerging Therapies: There's growing interest in synergistic effects of combining traditional materials with novel agents like statins and plant-derived extracts, suggesting a move towards multi-modal therapeutic approaches.
  • Placental Membranes as Future Scaffolds: Amnion (AM) and chorion (CM) membranes are highlighted as promising natural scaffolds due to their low immunogenicity, abundance of regenerative factors, and potential for large-scale application.
  • Nanohybrid Technology: The development of nanohybrid technologies, like PBNP-hybridized multicellular spheroids, offers innovative ways to enhance cell survival and promote bone repair in challenging environments.

Key Results

  • Increasing Trial Volume: The number of clinical trials in bone regeneration has significantly increased since 2018, averaging approximately 53.3 trials per year.
  • Dominant Bone Graft Materials: Synthetic bone substitutes (N=90) and xenografts (N=67) are the most common bone graft materials in clinical trials.
  • Barrier Membrane Landscape: Collagen membranes (N=53) remain dominant, but research is expanding to include other natural membranes (amniotic, chorionic), resorbable polyesters (N=24), titanium mesh (N=13), and nonresorbable PTFE membranes (N=11).
  • Bioactive Factor Usage: Platelet-Rich Fibrin (PRF) (N=71) is the most frequently used bioactive adjuvant.
  • Exploration of Synergies: Trials are exploring the combined effects of statins (N=17) and plant-derived active extracts (N=16) with other regenerative agents.

Limitations and Future Work

Limitations:

  • The study's findings are inherently limited by the quality, completeness, and reporting standards of the registered clinical trials.
  • The lack of publicly accessible clinical databases in certain regions restricts the comprehensiveness of the dataset.
  • A degree of subjectivity in assessing study eligibility was unavoidable, despite independent screening.
  • The landscape analysis describes trends and does not evaluate the efficacy of materials.

Future Work:

  • Optimizing Material Properties: Future research should focus on optimizing material degradation kinetics and spatial maintenance properties to enhance clinical outcomes.
  • Integrated Strategies: The development of integrated, multi-component strategies combining tunable scaffolds, growth factors, and small-molecule drugs is crucial for personalized and cost-effective bone defect repair.
  • Regulation of Microenvironment: Further research is needed to understand and regulate the integrated repair of bone and soft tissue, as well as the inflammatory microenvironment.
  • Rigorous Controlled Studies: Future rigorously designed and standardized controlled studies are essential to validate the true therapeutic effectiveness of different regenerative materials.

Summary updated

Abstract

Research on bone regeneration is undergoing a paradigm shift from the conventional "bone graft + barrier membrane" approach to integrated multicomponent strategies. These advanced strategies combine tunable biodegradable scaffolds, growth factors, and small-molecule drugs to achieve personalized and cost-effective bone defect repair. Future research priorities will focus on optimizing material degradation kinetics and spatial maintenance properties to enhance clinical outcomes.
BibTeX
@inproceedings{gui2025clinical,
  author = {Yuqing Gui and Xinyue Shen and Hongying Li and Jin Lou and Jiani Cao and Yu Jiang and Zhuojing Luo and Tianxiang Geng and Jingwei Xie},
  title = {{Clinical trial landscape for guided bone regeneration: trend analysis and future perspectives}},
  booktitle = {Frontiers in Dental Medicine},
  year = {2025},
  doi = {10.3389/fdmed.2025.1689513},
}
Figure